AstraZeneca shares fell 8.4 per cent on Tuesday as a corruption purge involving its China chief risked spiralling wider, clouding the outlook in the UK drugmaker’s second-largest market.
On Tuesday, Chinese publication Yicai reported that dozens of executives have been implicated in an investigation of medical insurance fraud.
The report came after AstraZeneca disclosed last week that its China president Leon Wang, a high-profile executive who has overseen a period of strong growth for the company, was co-operating with “an ongoing investigation by Chinese authorities”.
您已阅读9%（574字），剩余91%（5940字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。